Department of Neoplastic Diseases, The Mount Sinai School of Medicine, One Gustave L. Levy Place, New York, N.Y. 10029 U.S.A.
Abstract:
N-Phosphonoacetyl-l-aspartic acid (PALA), a potent inhibitor of aspartic acid transcarbamylase, is now undergoing Phase I clinical trials. Initial experiments revealed that PALA is not metabolized to phosphonoacetic acid (PAA) in humans. Thus PALA may be quantified in serum after in vitro conversion to PAA. Serum is deproteinized with perchloric acid, lipid extracted with methylene chloride, hydrolyzed with 8 N hydrochloric acid at 100° for 3 h, and evaporated to dryness with nitrogen. The residue is silylated, and PAA is quantified by monitoring the
